ChatGPT

Perplexity

Gemini

Claude

Grok

Bristol Myers Squibb’s Congress and Meetings event app. Use this app to keep updated on all details via real-time notifications.

BMS EVENTS is Bristol Myers Squibb's newest mobile app for digital engagement. Whether the event is virtual, hybrid, or in-person, use this global app at congresses and meetings to connect with your p

BMS World is a platform available to the Bristol Myers Squibb community to stay informed and connected. World gives you access to publicly available corporate content that is approved to share via you

Ensuring ethical conduct and quality across all interactions, making it a cornerstone of all operations and relationships with patients, healthcare providers, and partners.

Integrity

Acting swiftly and efficiently with the recognition that patients are waiting for life-changing treatments, demonstrated through accelerated research timelines and rapid development programs.

Urgency

All employees own Bristol Myers Squibb's success and strive to be transparent and deliver on commitments to patients, shareholders, and each other.

Accountability

Pursuing disruptive and bold solutions for patients through cutting-edge science, novel therapeutic modalities, and breakthrough medicines like Cobenfy.

Innovation

Embracing diversity and fostering an environment where all employees can work together at their full potential through People and Business Resource Groups.

Inclusion

Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a focus on oncology, cardiovascular, immunology, and hematology, BMS combines cutting-edge science with strategic acquisitions to advance patient care worldwide.

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership

Bristol-Myers Squibb acquisition of Celgene

Bristol-Myers Squibb to buy Celgene in $74B deal

Dr. Christopher Boerner

Board Chair and Chief Executive Officer

David V. Elkins

Executive Vice President and Chief Financial Officer

Sandra Leung

Executive Vice President and General Counsel

Adam Lenkowsky

Executive Vice President and Chief Commercialization Officer

Amanda Poole

Executive Vice President and Chief People Officer

Dr. Cristian Massacesi

Executive Vice President, Chief Medical Officer, and Head of Development

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.

https://en.wikipedia.org/wiki/Bristol_Myers_Squibb

Anticoagulant medication for patients with atrial fibrillation to reduce stroke risk, also used for treatment and prevention of deep vein thrombosis and pulmonary embolism. Shared with Pfizer, it's BMS's largest revenue generator at $13.3 billion annually.

Eliquis (apixaban)

Programmed death receptor-1 (PD-1) blocking antibody used to treat various cancers including unresectable or metastatic melanoma, metastatic non-small cell lung cancer, and multiple other tumor types. Generated $9.2 billion in 2024 revenue.

Opdivo (nivolumab)

Immunomodulatory drug used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes. Despite facing generic competition, it generated $5.8 billion in 2024.

Revlimid (lenalidomide)

Fixed-dose combination of nivolumab and relatlimab for treatment of unresectable or metastatic melanoma. Part of the Growth Portfolio with 62.7% revenue growth in 2024.

Opdualag

First-in-class erythroid maturation agent for treating anemia in adults with beta thalassemia and myelodysplastic syndromes. Showed 80% year-over-year growth in 2024.

Reblozyl (luspatercept)

CD19-directed CAR-T cell therapy for adults with relapsed or refractory large B-cell lymphoma and chronic lymphocytic leukemia. Experienced 50% growth in 2024 due to expanded manufacturing.

Breyanzi (lisocabtagene maraleucel)

B-cell maturation antigen (BCMA)-directed CAR-T cell therapy for relapsed or refractory multiple myeloma after two or more prior lines of therapy.

Abecma (idecabtagene vicleucel)

The first novel treatment for schizophrenia in 70 years, developed by Karuna Therapeutics and acquired by BMS. Offers a new mechanism of action for this debilitating chronic mental disorder.

Cobenfy

First-in-class cardiac myosin inhibitor for treatment of symptomatic obstructive hypertrophic cardiomyopathy. FDA simplified monitoring requirements in 2024.

Camzyos (mavacamten)

T-cell co-stimulation modulator for treatment of autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis.

Orencia (abatacept)

BMS announced Q4 and full-year 2024 results showing revenues of $48.3 billion, up 7% year-over-year (9% adjusting for FX). The Growth Portfolio reached $22.6 billion with 17% growth. Eliquis generated $13.3 billion, Opdivo $9.2 billion, and the new product portfolio grew 77% to $3.6 billion led by Reblozyl, Opdualag, Breyanzi, and Cobenfy.

Bristol Myers Squibb Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

BMS completed the acquisition of Cambridge-based 2seventy bio, a developer of cellular therapies for cancer treatment, for approximately $286 million. This acquisition strengthens BMS's position in the rapidly growing CAR-T cell therapy market, complementing existing therapies Breyanzi and Abecma.

Bristol Myers Squibb Acquires 2seventy bio to Strengthen CAR-T Portfolio

Bristol Myers Squibb presented updated Phase 1 Breakfree-1 data for autologous CD19 NEX-T CAR T therapy BMS-986353, showing robust CAR-T expansion across 71 treated patients. Remarkably, 94% of patients remained off chronic immunosuppressive therapy, demonstrating the potential for durable responses without ongoing treatment.

BMS Presents Breakthrough CAR-T Data Showing 94% of Patients Off Immunosuppressive Therapy

The U.S. FDA approved Cobenfy (KarXT) for the treatment of schizophrenia, marking the first novel type of treatment for this debilitating chronic mental disorder in more than seven decades. The drug came from BMS's $14 billion acquisition of Karuna Therapeutics and offers a new mechanism of action beyond traditional antipsychotics.

FDA Approves Cobenfy, First Novel Schizophrenia Treatment in 70 Years

insitro and Bristol Myers Squibb extended their strategic collaboration to apply insitro's ChemML™ platform toward discovery of small-molecule therapies for amyotrophic lateral sclerosis (ALS). BMS committed up to $20 million in new funding to support the research program targeting this devastating neurodegenerative disease.

insitro and Bristol Myers Squibb Extend ALS Collaboration with $20M Funding

The FDA accepted Bristol Myers Squibb's supplemental Biologics License Applications (sBLAs) for Breyanzi in follicular lymphoma and mantle cell lymphoma for priority review. Key pipeline advances include U.S. FDA approval of Augtyro for solid tumors and continued expansion of the CAR-T therapy's approved indications.

FDA Grants Priority Review for Breyanzi in Follicular Lymphoma and Mantle Cell Lymphoma

Bristol Myers Squibb was recognized in the Dow Jones Best-in-Class index for the second consecutive year, highlighting the company's commitment to sustainability, corporate governance, and ethical business practices. The company also maintained its status as a Military Friendly Employer and Certified Age-Friendly Employer.

BMS Named to Dow Jones Best-in-Class Index for Second Consecutive Year

Former Bristol Myer Squibb Worker with a Federal Suit — Looking for Witnesses Who Faced Discrimination or Misclassification

Is Bristol-Myers Squibb portfolio and pipeline strength really that bad?

Am I getting scammed here?

Bristol Myers Squibb and Microsoft launch a joint AI program for early lung cancer detection in U.S. hospitals

Bristol Myers Squibb extended CCR8 study completion from 12/2026 to 07/2028 - I will take it as a good sign

What’s the best location for Bristol Myers’s Squibb (BMS) ?

Kleiner reminder das Bristol Myers Squibb gerade sehr nach cup with handle aussieht

biotech

jobs

CHRS

careerguidance

wallstreetbetsGER

BRISTOL MYERS SQUIBB CO

Edward Robinson Squibb established the Squibb corporation in Brooklyn, New York, pioneering quality control and high purity standards in pharmaceutical manufacturing.

Squibb Corporation Founded

William McLaren Bristol and John Ripley Myers, Hamilton College graduates, purchased Clinton Pharmaceutical Company in Clinton, New York for $10,000, laying the foundation for Bristol-Myers.

Bristol-Myers Founded

The landmark merger of Bristol-Myers and Squibb created Bristol-Myers Squibb, forming the second-largest pharmaceutical company in the world at the time.

Bristol-Myers and Squibb Merge

BMS acquired biotechnology firm Medarex as part of the company's 'String of Pearls' strategy of alliances, partnerships, and acquisitions to strengthen its biologics pipeline.

Medarex Acquisition

BMS agreed to buy Amylin Pharmaceuticals for $5.3 billion in cash and paid Eli Lilly $1.7 billion to cover Amylin's debt, expanding its diabetes treatment portfolio.

Amylin Pharmaceuticals Acquisition

Giovanni Caforio, formerly the company's COO, became CEO, succeeding Lamberto Andreotti upon his retirement and leading BMS through a transformative decade.

Giovanni Caforio Becomes CEO

BMS acquired IFM Therapeutics for $300 million upfront with $1.01 billion in milestone payments, strengthening its position to compete against Merck's Keytruda in oncology.

IFM Therapeutics Acquisition

BMS completed the acquisition of Celgene for $74 billion ($95 billion including debt), one of the largest pharmaceutical deals in history, adding Revlimid and other blockbuster drugs.

Celgene Mega-Acquisition

Dr. Christopher Boerner was appointed CEO, succeeding Giovanni Caforio and bringing fresh strategic vision for BMS's next chapter of growth and innovation.

Christopher Boerner Named CEO

BMS acquired Mirati Therapeutics, developer of targeted cancer therapies, for $4.8 billion plus $1 billion in milestone payments, adding Krazati to its oncology portfolio.

Mirati Therapeutics Acquisition

BMS acquired RayzeBio for approximately $4.1 billion, adding actinium-based radiopharmaceuticals and enhanced radiopharma manufacturing infrastructure to its capabilities.

RayzeBio Acquisition

BMS acquired Karuna Therapeutics for $14 billion, gaining Cobenfy, which would become the first novel schizophrenia treatment approved in 70 years.

Karuna Therapeutics Acquisition

Dr. Boerner was elected Board Chair, succeeding Dr. Giovanni Caforio who retired after 23 years of service, consolidating leadership under the new CEO.

Christopher Boerner Becomes Board Chair

The FDA approved Cobenfy, the first novel type of treatment for schizophrenia in more than 70 years, representing a major breakthrough in mental health treatment.

FDA Approves Cobenfy for Schizophrenia

BMS acquired 2seventy bio, a Cambridge-based developer of cellular therapies for cancer treatment, for $286 million, strengthening its CAR-T therapy portfolio.

2seventy bio Acquisition

For use with the engineering kits “Robotics: Smart Machines”, “Robotics: Smart Machines - Rovers & Vehicles Edition”, and “Robotics: Smart Machines - Tracks & Treads Edition” by Thames & Kosmos.

This

The Blue Alliance is a tool to help FIRST Robotics teams scout for, compete at, and relive competitions.

The Blue Alliance app is the easiest way to access all the great content on thebluealliance.co

1. Smart connection, multi-device management. 
2. Share with your family, a more relaxed lifestyle. 
3. Support OTA remote upgrade. 
4. Duration The working time of the Robotic Pool Cleaner can be set

Bucket Robotics is an AI defect detection platform from YC batch making defect detection faster more deployable starting with 250M lbs plastic wasted annually in US manufacturing turning CAD files into defect detectors using AI vision for quality control enabling manufacturers reduce waste improve quality targeting manufacturers through AI defect detection YC batch.

Bristol Myers Squibb vs Bucket Robotics

Bristol Myers Squibb

About

Bucket Robotics

About

AI Visibility Head-to-Head

Also Compare

Track AI Visibility in Real Time